No Data
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Phase III clinical study of recombinant human thrombopoietin injection (TPO) in the treatment of chronic liver disease-related thrombocytopenia achieved the preset primary endpoint.
Shenyang, July 26, 2024 / PRNewswire/ -- 3sbio (01530.HK) announced today that the phase III clinical study (Project Number: TPO106) of Recombinant Human Thrombopoietin Injection (Trade name: TPIAO) for the treatment of chronic liver disease-associated thrombocytopenia in patients undergoing elective invasive surgery has been completed and the results have achieved the pre-specified primary endpoint. 3sbio plans to submit a new indication application to the National Medical Products Administration in the near future. The primary efficacy endpoint of this phase III clinical trial is to verify the Recombinant Human Thrombopoietin Injection (
3SBio (HKG:1530) Investors Are Sitting on a Loss of 48% If They Invested Five Years Ago
3sbio has submitted the application for the marketing of SSS06, a recombinant erythropoietin stimulating protein injection, to the National Medical Products Administration and it has been accepted.
Shenyang, July 12, 2024 / PRNewswire / - 3SBio (1530.HK) announced today that its independently developed long-acting erythropoietin product, recombinant erythropoietin stimulating protein injection SSS06, has submitted a listing application to the National Medical Products Administration and received acceptance, which is used to treat adult hemodialysis patients receiving erythropoiesis-stimulating agent treatment. In January of this year, the company announced that the Phase III clinical trial of the product had achieved the predetermined primary endpoint. Anemia is a common complication of chronic kidney disease (CKD). Due to endogenous erythropoietin deficiency,
Investors Don't See Light At End Of 3SBio Inc.'s (HKG:1530) TunnelNo Data
